ASX Announcements
Notification of cessation of securities - CSL
Appendix 3H (Notification of cessation of securities)
- Dec 9, 2024
- 4 pages
Notification regarding unquoted securities - CSL
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities)
- Dec 5, 2024
- 5 pages
Application for quotation of securities - CSL
Appendix 2A (Application for Quotation of Securities)
- Dec 3, 2024
- 6 pages
This Month
Australia’s 50 highest-paid CEOs in 2024 revealed
Macquarie Group’s Shemara Wikramanayake is Australia’s best-paid CEO for the fourth year in a row.
- Patrick Durkin
November
CSL tumbles as investors fear RFK jnr’s vaccine plans
The White House appointment of the anti-vax conspiracy theorist is devastating ASX healthcare and biotech shares as he threatens to turn the FDA ‘on its head’.
- Updated
- Joshua Peach and Joanne Tran
- Research Winner
- Best Universities Ranking
Stellar records on research at risk from funding shortfall
Melbourne University, ranked No.1 in the Research category, has created an ecosystem with industry partners and policymakers.
- Alexandra Cain
- Exclusive
- Big four consultants
Deloitte board nominates Joanne Gorton as preferred CEO
The firm’s head of audit has been selected as the preferred candidate to replace chief executive Adam Powick.
- Edmund Tadros
October
Investors turn on CSL, delivering first strike on pay after poor year
But the company told shareholders it needed to compete with major rivals in the US for talent, and had to pay higher salaries to keep key executives.
- Michael Smith
Telix boss says Australia ‘horrible’ at getting drugs to patients
Christian Behrenbruch, the founder of ASX biotech giant Telix, says Australia has a “horrible” track record getting drugs to patients and lags rest of the world.
- Michael Smith
2024’s most powerful and influential directors revealed
As AGM season gathers pace, the BOSS index of the country’s most powerful and influential directors reveals a new cohort rising through the ranks.
- Patrick Durkin
CSL pulls studies, trials on three therapies in late-stage setback
The biotech giant has not ruled out expanding its pipeline of treatments through acquisitions after a number of projects were put on hold.
- Michael Smith
Why CSL’s earnings outrun CBA, according to this value investor
Investors Mutual’s Daniel Moore says there aren’t too many ASX-listed companies like blood plasma giant CSL that can compound their earnings at such a rate.
- Joanne Tran
Victoria slumps for business, as execs warn: ‘It’s really struggling’
CSL chairman Brian McNamee and former NAB CEO Ross McEwan warn that the state is in financial peril, as new business starts fell behind the rest of the country.
- Gus McCubbing and Patrick Durkin
September
- Opinion
- Investing
How Australia’s ‘magnificent 10’ contributed to returns over 20 years
How costly was failing to pick the ASX’s 10 top performers over the past two decades? Vanguard did the sums
- Carole Okigbo
August
- Updated
- Earnings season
CSL’s bullish earnings call dimmed by stumbles at new Vifor business
The country’s largest pharmaceutical company says it expects double-digit earnings growth for the next five years as its core blood products business surges.
- Updated
- Michael Smith
- Opinion
- Chanticleer
‘I want to win every time’: The Olympic-style goal driving CSL’s boss
The company’s growth forecasts for next year are a touch weaker than the market expected. But inspired by the Games, CEO Paul McKenzie is focused on another goal.
- Updated
- James Thomson
- Results Wrap
- Chanticleer
How Temple & Webster won day two of profit season
CSL was the headline result, but it was Seek which was hit hardest on results day. Here’s what caught our eye.
- James Thomson and Anthony Macdonald
US eyes Iran attack; Musk interviews Trump; Airtrunk’s $20b tax test
Read everything that’s happened in the news so far today.
July
CSL wins global avian flu vaccine contracts
Australian pharmaceutical giant CSL is to supply up to 45 million shots of its avian flu vaccine to Europe and the US as health authorities prepare for possible human infection from the dangerous H5 strain.
- Tom Burton
- Opinion
- Investing
How to invest in the golden age of health disruption
Investing in healthcare in today’s market combines exposure to two key drivers – structural demand growth and disruptive innovation.
- Andrew McAuley
June
Woolworths, CSL among ASX giants that should sell foreign assets
A wave of Australian companies are ditching their overseas businesses to bring capital back to Australia. MST Marquee says there are more that should do the same.
- Alex Gluyas
A biotech boom for the ASX? This fundie thinks so
SG Hiscock’s Rory Hunter thinks CSL could “absolutely” hit $500, says biotechs are ripe for M&A, and reveals a hidden gem flying under the market’s radar.
- Alex Gluyas
- Exclusive
- Funding
Super funds, CSL pour $270m into venture capital fund
Australia’s largest life science investment fund, Brandon Capital, has banked $270 million of a planned $350 million raise for its sixth VC fund.
- Updated
- Tess Bennett